Genelux Corp($GNLX) is a clinical-stage biopharmaceutical company. The company is focused on developing next-generation oncolytic viral immunotherapies for the treatment of aggressive or refractory solid tumors. Genelux is advancing a Phase II trial of Olvi-Vec in patients with non-small cell lung cancer (NSCLC), with interim data expected in mid-2025. In addition, the company is conducting a Phase III trial of Olvi-Vec in combination with chemotherapy for ovarian cancer.
Buy rating.
Target price: $5+.
Weekly Featured Inventory
Long-term high-quality recommendations for December 2024($GNLX)
